C Hobson1, C Le Brun1, C Beauruelle1,2, Z Maakaroun-Vermesse3, L Mereghetti1,2, A Goudeau1, P Lanotte2,1. 1. CHRU de Tours, Service de Bactériologie-Virologie, F-37044 Tours, France. 2. ISP, INRA, Université François Rabelais de Tours, UMR 1282, F-37380, Nouzilly, France. 3. CHRU de Tours, Service de Médecine et Maladies Infectieuses, F-37044 Tours, France.
Abstract
PURPOSE: Bartonella is an increasingly isolated emerging pathogen that can cause severe illness in humans, including cat scratch disease (CSD). The bacteria are difficult to grow and thus many detection methods have been developed, especially molecular. We previously developed a PCR method targeting ribC to identify Bartonella sp. A manufactured kit (RealCycler BART, Progenie Molecular) was commercialised shortly thereafter for the detection of Bartonella infection, including Bartonella henselae. METHODOLOGY: We performed a comparison between this test and our in-house PCR assay on 73 lymphadenopathy samples sent to the laboratory for suspicion of CSD.Results/Key findings. Among the 28 positive samples for Bartonella, 21 were identified by the two PCR assays, and seven by the commercial kit only. CONCLUSION: The performance of this commercial kit suggests that it could be a suitable alternative to our in-house PCR assay, highlighting the importance of the molecular methods used to diagnose CSD.
PURPOSE:Bartonella is an increasingly isolated emerging pathogen that can cause severe illness in humans, including cat scratch disease (CSD). The bacteria are difficult to grow and thus many detection methods have been developed, especially molecular. We previously developed a PCR method targeting ribC to identify Bartonella sp. A manufactured kit (RealCycler BART, Progenie Molecular) was commercialised shortly thereafter for the detection of Bartonella infection, including Bartonella henselae. METHODOLOGY: We performed a comparison between this test and our in-house PCR assay on 73 lymphadenopathy samples sent to the laboratory for suspicion of CSD.Results/Key findings. Among the 28 positive samples for Bartonella, 21 were identified by the two PCR assays, and seven by the commercial kit only. CONCLUSION: The performance of this commercial kit suggests that it could be a suitable alternative to our in-house PCR assay, highlighting the importance of the molecular methods used to diagnose CSD.
Authors: Diana J Vaca; Gerhard Dobler; Silke F Fischer; Christian Keller; Maik Konrad; Friederike D von Loewenich; Sylvain Orenga; Siddhesh U Sapre; Alex van Belkum; Volkhard A J Kempf Journal: FEMS Microbiol Rev Date: 2022-07-20 Impact factor: 15.177